With Its Hypertension Franchise in Crisis, Novartis Restructures
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.